The work received support from the Public Health Service (R01 NS108773, F32 CA224593), a Defeat DIPG Research Grant and the V Foundation.Īuthors Gromeier, Dobrikova, Brown, Nair, Bigner and Ashley are co-inventors of intellectual property for the PVSRIPO therapy that was licensed to Istari Oncology. It is recognized worldwide that over 1000 children die every year following being diagnosed with a specific brain cancer called Diffuse Intrinsic Pontine Glioma. Brown, Yuanfan Yang, Jana Cable, Hideho Okada, Smita K. In addition to Gromeier, study authors Mubeen M. “We are hopeful that this approach could be tested as a potential therapy for DMG tumors, which exact a terrible burden on children and their families,” Gromeier said. Gromeier said the vaccine approach continues to be tested with the goal of initiating a phase 1 clinical trial. As a result, they lack interference with innate or adaptive immunity.” “They have naturally evolved to have a relationship with the human immune system, activating dendritic cells, inducing CD8 T-cell immunity and eliciting inflammation. “Polioviruses have several advantages for generating antigen-specific CD8 T-cells as a potential cancer vaccine vector,” said senior author Matthias Gromeier, MD, who developed the poliovirus-based therapy as a member of the Preston Robert Tisch Brain Tumor Center.ĭuke researchers use the modified virus to spur natural immune attack against tumors in animal studies Combination of surgery (if amenable to surgery), radiotherapy, and chemotherapy based on comprehensive multidisciplinary discussion can be considered as the treatment options for DMG. But their activity can be difficult to control. The detection of H3K27M mutation is the most important diagnostic criteria for DMG. Reporting this week in the journal Nature Communications, the researchers described how a polio-rhinovirus chimera (PVSRIPO), modified to express a mutate tumor antigen found in DMG, is able to infect and induce the activity of dendritic cells.ĭendritic cells prime tumor antigen-specific T-cells to migrate to the tumor site, attack tumor cells, delay tumor growth and enhance survival in animal tumor models. The cancer strikes children and is universally deadly. In preclinical studies using mice and human cancer cells, an injection of the modified poliovirus vector instigated an immune response that homed in on mutated cancer cells that predominate in diffuse midline glioma (DMG) tumors. A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for pediatric brain tumors when used as part of a cancer vaccine. Disease Management Group (DMG) is the hallmark of oncology care at Medanta. There have been no guidelines for the management of adult patients with diffuse midline glioma (DMG), H3K27M-mutant in Korea since the 2016 revised WHO.
0 kommentar(er)
